US20150185232A1 - Innate immune proteins as biomarkers for cns injury - Google Patents

Innate immune proteins as biomarkers for cns injury Download PDF

Info

Publication number
US20150185232A1
US20150185232A1 US14/376,383 US201314376383A US2015185232A1 US 20150185232 A1 US20150185232 A1 US 20150185232A1 US 201314376383 A US201314376383 A US 201314376383A US 2015185232 A1 US2015185232 A1 US 2015185232A1
Authority
US
United States
Prior art keywords
protein
injury
inflammasome
patient
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/376,383
Other languages
English (en)
Inventor
Robert W. Keane
W. Dalton Dietrich
Juan Pablo De Rivero Vaccari
Stephanie Adamczak
M. Ross Bullock
Allan Levi
Michael Y. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Priority to US14/376,383 priority Critical patent/US20150185232A1/en
Publication of US20150185232A1 publication Critical patent/US20150185232A1/en
Assigned to UNIVERSITY OF MIAMI reassignment UNIVERSITY OF MIAMI ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEVI, Allan, WANG, MICHAEL Y., ADAMCZAK, STEPHANIE E., BULLOCK, ROSS, DE RIVERO VACCARI, JUAN PABLO, DIETRICH, W. DALTON, KEANE, ROBERT W.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Definitions

  • the present invention relates generally to the fields of neurology, immunology, and diagnostics.
  • the present invention relates to the identification of biomarkers in biological samples which can predict the severity of neuronal injury, such as spinal cord and traumatic brain injury, in patients.
  • the identified biomarkers may also be used in determining prognosis, directing therapeutic and rehabilitation efforts, and monitoring response to treatment for patients with a central nervous system injury.
  • Nucleotide-binding oligomerization domain (NOD)-containing protein-like receptors (NLRs) are a recently discovered class of innate immune receptors that play a crucial role in initiating inflammatory responses following tissue injury in the central nervous system (CNS) (Abulafia et al., 2009, Silverman et al., 2009).
  • NLRP1 also known as NAcht leucine-rich-repeat protein 1 (NALP-1)
  • ASC caspase recruitment domain
  • SCI spinal cord injury
  • TBI traumatic brain injury
  • inflammasomes are induced by physical damage to the plasma membrane, and by certain endogenous ligands referred to as danger associated molecular patterns (DAMPs) or exogenous ligands known as pathogen associated molecular patterns (PAMPs) (Bianchi, 2007, Wakefield et al., 2010).
  • DAMPs danger associated molecular patterns
  • PAMPs pathogen associated molecular patterns
  • TLRs Toll-like receptors
  • purinergic ATP-gated receptors which induce the transcription of pro-IL-1 ⁇ .
  • Hyperinflammatory responses associated with tissue damage can promote pathogenesis of SCI and TBI via overproduction of IL-1 ⁇ and other potentially neurotoxic products.
  • Inflammasome-mediated IL-1 ⁇ overproduction is involved in the pathogenesis of type 2 diabetes, liver damage and muscular dystrophy (Kufer and Sansonetti, 2011).
  • inflammasome activation could also drive adaptive immunity in types of dermatitis, skin related allergies and asthma (Kufer and Sansonetti, 2011).
  • inflammasome components may be secreted into the extracellular milieu via a mechanism involving the exosome pathway (Bianchi, 2007). The inflammasome therefore has a complex connection with the control of adaptive immune responses that has become the subject of intense investigation. Whether inflammasomes are associated with tissue destructive inflammatory processes after SCI and TBI in humans has not been investigated.
  • TBI affects an estimated 1.5 million people each year and causes one-third of injury-related deaths. Approximately 5.3 million Americans are living today with a permanent TBI-related disability. Predicting the severity and outcome of TBI and well as SCI is difficult, given the lack of objective, laboratory-based biomarkers.
  • GCS Glasgow Coma Scale
  • the Glasgow Coma Scale (GCS) score (Teasdale et al., 1974) is the best available clinical predictor of injury severity; however, its value is limited in patients undergoing pharmacological paralysis for intubation, as a motor score cannot be obtained (Brain Trauma Foundation, American Association of Neurological Surgeons, 2000). Predicting outcome is further complicated by the heterogeneity of pathology in patients with a similar GCS score.
  • biomarkers S-100 ⁇ , neuron-specific enolase, neurofilament light chain and glial fibrillary acidic protein are significantly increased in cases of SCI in experimental animals studies (Skouen et al., 1999, Ma et al., 2001, Nagy et al., 2002, Cornefjord et al., 2004, Loy et al., 2005, Cao et al., 2008, Pouw et al., 2009). Although some biomarkers show promising results, these do not yet provide a sensitive prognostic tool. Quantitative standards for determining the extent of SCI and TBI during the acute phase must be developed and validated.
  • CSF cerebrospinal fluid
  • the present invention is based, in part, on the discovery that NLRP1 (NALP-1) inflammasome components are secreted into the cerebrospinal fluid (CSF) acutely after SCI and traumatic brain injury (TBI) in humans. Elevated inflammasome protein levels in the CSF following central nervous system (CNS) injury represent the degree of neuroinflammation in CNS tissue and reflect the extent of inflammatory-induced damage. The CSF levels of inflammasome protein following injury correlate with the degree of functional recovery in patients and thus, can be used as acute biomarkers to predict patient prognosis and direct therapeutic interventions. Accordingly, the present invention provides a method of assessing the severity of a CNS injury in a patient.
  • CNS central nervous system
  • the invention provides a method of evaluating a patient suspected of having a CNS injury comprising providing a biological sample from a patient presenting with clinical symptoms consistent with a CNS injury, measuring the level of at least one inflammasome protein in the biological sample, determining the presence or absence of a protein signature associated with a CNS injury or a more severe CNS injury, wherein the protein signature comprises an elevated level of said at least one inflammasome protein, and selecting patients exhibiting the presence of the protein signature as having a CNS injury or a more severe CNS injury.
  • said one or more inflammasome proteins are NLRP1 (NALP-1), ASC, or caspase-1.
  • the diagnostic methods of the invention may further comprise administering a neuroprotective treatment to the patient based on the measured level of one or more inflammasome proteins, and following changes in the level of one or more inflammasome proteins as a mechanism to monitor response to treatment.
  • the levels of one or more inflammasome proteins in the patient's sample can be used to prepare an inflammasome protein profile associated with CNS injury.
  • the levels of inflammasome proteins in the profile may be determined relative to levels of the proteins in control samples or pre-determined reference values or ranges of reference values.
  • the inflammasome protein profiles are, in some embodiments, indicative of the presence or severity of CNS injury in a patient. When such protein profiles are prepared from samples obtained from patients following administration of a neuroprotective treatment, the inflammasome protein profiles are indicative of therapeutic efficacy of the neuroprotective treatment in the patient.
  • the present invention also provides a method of determining a prognosis for a patient with a central nervous system injury.
  • the method comprises providing a biological sample, such as cerebrospinal fluid, obtained from the patient shortly after injury (e.g., within a week of injury), and measuring the level of at least one inflammasome protein in the biological sample to prepare an inflammasome protein profile, wherein the inflammasome protein profile is indicative of the prognosis of the patient.
  • an elevated level of at least one inflammasome protein relative to a pre-determined reference value or range of reference values is indicative of a poorer prognosis or unfavorable patient outcome.
  • example elevated inflammasome protein levels are predictive of the patient having a Glasgow Outcome Scale (GOS) score of 1 to 3 upon follow-up assessment.
  • GOS Glasgow Outcome Scale
  • a reduced level of at least one inflammasome protein relative to a pre-determined reference value or range of reference values is predictive of a favorable patient outcome (e.g. GOS score of 4 or 5 upon follow-up assessment).
  • the method provides a prognosis for a patient with a spinal cord or traumatic brain injury.
  • kits for preparing an inflammasome protein profile associated with CNS injury comprises a labeled-binding partner, such as labeled-antibody or fragment thereof, that specifically binds to one or more inflammasome proteins, wherein said one or more inflammasome proteins are selected from the group consisting of NLRP1, ASC, caspase-1, and combinations thereof.
  • FIG. 1 NLRP1, ASC, and Caspase-1 are biomarkers that predict outcome after SCI.
  • CSF samples were immunoblotted with antibodies against NLRP 1, caspase-1 and ASC.
  • CSF samples from uninjured patients were used as controls. Immunoblot analysis of 6 different cases of patients with SCI indicates that patients (2, 3 and 4) who express low levels of caspase-1 acutely after SCI have a better prognosis than subjects (1, 5 and 6) who have elevated levels of this protein in CSF.
  • FIG. 2 NLRP1 inflammasome proteins are expressed in cells of the CNS. Spinal cord sections were obtained from decedents that had injury to the spinal cord. Immunohistochemical analysis combined with light microscopy indicates that NLRP1 is expressed in neurons of the ventral horn (black arrows) myelinated axons (black arrow heads) and oligodendrocytes (yellow arrows) (top panel). Caspase-1 is expressed in swollen axons (spheroids, blue arrows), motor neurons (black arrows) and in oligodendrocytes (yellow arrows) (central panel). ASC is present in neurons in the ventral horn (black arrows), white matter oligodendrocytes (yellow arrow) and macrophages/microglia (blue arrow heads) (bottom panel).
  • FIG. 3 Scatter plots of expression of inflammasome proteins in controls and patients with TBI.
  • Samples were immunoblotted for ASC (A), caspase-1 (B), and NALP-1 (C).
  • the p values in the upper left corner represent results of a Mann-Whitney U-test.
  • FIG. 4 Box plots of expression of inflammasome proteins sorted by outcome category. The ends of the whiskers represent the lowest datum within 1.5 interquartile range of the lower quartile and the highest datum within 1.5 interquartile range of the upper quartile. The asterisks represent the outliers. Mann-Whitney U-tests indicate higher expression of ASC (A), caspase-1 (p20) (B), and NALP-1 (C) are significantly associated with an unfavorable outcome 5 months after injury (p ⁇ 0.0001). Representative immunoblots for each protein are shown. Samples were run on the same gel but were noncontiguous.
  • FIG. 5 Scatter plots and estimated linear regression of ASC (A), caspase-1 (p20) (B), and NALP-1 (C) expression in the CSF with GOS score. Probability values of the linear regression are shown in the top left of each graph. Expression of each protein correlated significantly with GOS score at 5 months post-injury. The p values on the x axis represent post hoc comparisons of a Kruskal-Wallis test. Representative immunoblots are shown. Samples were run on the same gel but were noncontiguous.
  • FIG. 6 Caspase-1 levels in CSF one, two, and three days following TBI in pediatric patients receiving hypothermia treatment or no treatment (normothermia).
  • the present invention is based, in part, on the discovery that NLRP1 inflammasomes play an important role in inflammatory responses after SCI and TBI in humans.
  • the present inventors have surprisingly found that nucleotide-binding leucine-rich repeat pyrin domain containing protein 1 (NLRP1), the adaptor protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and caspase-1 are secreted into the cerebrospinal fluid (CSF) of human patients following SCI and TBI.
  • NLRP1 nucleotide-binding leucine-rich repeat pyrin domain containing protein 1
  • ASC caspase recruitment domain
  • caspase-1 caspase-1
  • the present invention provides a method of assessing the severity of a central nervous system injury in a patient by measuring the level of at least one inflammasome protein in a biological sample obtained from the patient, wherein the measured level of said at least one inflammasome protein is indicative of the severity of the central nervous system injury in the patient.
  • inflammasome refers to a multi-protein complex that activates caspase-1 activity, which in turn regulates IL-1 ⁇ , IL-18 and IL-33 processing and activation. See Arend et al. 2008; Li et al. 2008; and Martinon et al. 2002, each of which is incorporated by reference in their entireties.
  • An “inflammasome protein” is a protein component of inflammasome complexes and can include, but is not limited to, an nucleotide binding domain, leucine-rich repeat containing (NLR) family member (e.g.
  • the method comprises measuring an inflammasome protein selected from the group consisting of NLRP1 (NALP-1), ASC, caspase-1, or combinations thereof. In one embodiment, the p20 subunit of active caspase-1 is measured.
  • patient or “subject” are used interchangeably herein, and is meant a mammalian subject to be treated, with human patients being preferred.
  • the patient is a pediatric patient.
  • Pediatric patients include newborns (birth to 1 month of age), infants (1 month to 2 years of age), children (2 to 12 years of age), and adolescents (12-21 years of age).
  • the methods of the invention find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters, and primates.
  • the present invention provides a method of evaluating a patient suspected of having a central nervous system (CNS) injury.
  • the method comprises providing a biological sample from a patient presenting with clinical symptoms consistent with a CNS injury; measuring the level of at least one inflammasome protein in the biological sample; determining the presence or absence of a protein signature associated with a CNS injury or a more severe CNS injury, wherein the protein signature comprises an elevated level of said at least one inflammasome protein; and selecting patients exhibiting the presence of the protein signature as having a CNS injury or a more severe CNS injury.
  • a patient may be suspected of having a CNS injury on the basis of neurologic symptoms (motor, sensory, cognitive) and/or radiological evaluation (MRI, CT scan, X-ray) consistent with a CNS injury, e.g., after a physician's exam.
  • a patient suspected of having a CNS injury, particularly a spinal cord injury may having a rating of A or B on the American Spinal Cord Injury Association (ASIA) Impairment Scale.
  • ASIA Impairment Scale is a standard diagnostic tool that assess a patient's motor and sensory function. The classification ratings and accompanying descriptions of the ASIA Impairment Scale are as follows:
  • a patient suspected of having a CNS injury may have a score of ⁇ 12 (e.g. 3 to 12) on the Glasgow Coma Scale (GCS).
  • the patient may have a GCS score of ⁇ 8 (e.g. 3 to 8).
  • the GCS is a neurological scale commonly used to assess the level of consciousness of patients after injury or trauma. The scale is composed of three tests (eye, verbal and motor responses), each of which is assigned a value on a scale up to 6. The three values separately as well as their sum are considered. The lowest possible GCS score (the sum) is 3 (deep coma or death), while the highest is 15 (fully awake person).
  • a GCS score ⁇ 9 is indicative of severe brain injury whereas a GCS score ⁇ 13 is indicative of minor brain injury.
  • a GCS score between 9-12 is generally indicative of a moderate brain injury.
  • a patient suspected of having a CNS injury may have one or more signs and symptoms of CNS injury, such as temporary loss of consciousness, confusion, disorientation, memory or concentration problems, headache, dizziness, loss of balance, nausea or vomiting, sensory disruptions (e.g. blurred vision, ringing in the ears, bad taste in the mouth, loss of sensation in limbs), loss of motor function, sensitivity to light or sound, mood changes or mood swings, depression or anxiety, fatigue, drowsiness, and sleep disturbances.
  • signs and symptoms of CNS injury such as temporary loss of consciousness, confusion, disorientation, memory or concentration problems, headache, dizziness, loss of balance, nausea or vomiting, sensory disruptions (e.g. blurred vision, ringing in the ears, bad taste in the mouth, loss of sensation in limbs), loss of motor function, sensitivity to light or sound, mood changes or mood swings, depression or anxiety, fatigue, drowsiness, and sleep disturbances.
  • the level, concentration, or abundance of one or more inflammasome proteins is measured in a biological sample obtained from a patient (e.g. a patient suspected of having or suffering from a CNS injury).
  • the levels, concentrations, or abundance of one or more inflammasome proteins is indicative of the severity of CNS injury in the patient.
  • a CNS injury includes, but is not limited to, a traumatic brain injury, a stroke-related injury, a cerebral aneurism-related injury, a spinal cord injury (e.g.
  • the levels, concentrations, or abundance of one or more inflammasome proteins is indicative of the severity of traumatic brain injury or spinal cord injury in the patient.
  • biological sample refers to any bodily fluid or tissue obtained from a patient or subject.
  • a biological sample can include, but is not limited to, whole blood, red blood cells, plasma, serum, peripheral blood mononuclear cells (PBMCs), urine, saliva, tears, buccal swabs, CSF, CNS microdialysate, and nerve tissue.
  • the biological sample is CSF, saliva, serum, plasma, or urine.
  • the biological sample is CSF.
  • the measured level, concentration, or abundance of one or more inflammasome proteins in the biological sample is used to prepare an inflammasome protein profile, wherein the profile is indicative of the severity of a CNS injury in the patient or the patient's prognosis or recovery potential from a CNS injury.
  • the inflammasome protein profile may comprise the level, abundance, or concentration of one or more inflammasome proteins measured in the patient's sample optionally in relation to a pre-determined value or range of reference values as described herein.
  • the inflammasome proteins in the profile include NLRP1 (NALP-1), ASC, and/or caspase-1 (e.g. p20 subunit of caspase-1).
  • the inflammasome protein profile comprises the level, abundance, or concentration of each of NLRP1 (NALP-1), ASC, and caspase-1 (e.g. p20 subunit of caspase-1).
  • the method of evaluating a patient suspected of having a CNS injury comprises determining the presence or absence of a protein signature associated with a CNS injury or a more severe CNS injury based on the measured level, abundance, or concentration of one or more inflammasome proteins in the patient sample or on the inflammasome protein profile prepared from the patient's sample.
  • the protein signature comprises an elevated level of at least one inflammasome protein.
  • the level of said at least one inflammasome protein in the protein signature may be enhanced relative to the level of the protein in a control sample or relative to a pre-determined reference value or range of reference values as further described herein.
  • the protein signature may, in certain embodiments, comprise an elevated level for each of caspase-1 (e.g. p20 subunit of caspase-1), NLRP1, and ASC. Patients who exhibit the protein signature may be selected or identified as having a CNS injury or a more severe CNS injury.
  • the level or concentration of at least one inflammasome protein can be assessed at a single time point (e.g. after a potential CNS injury) and compared to a pre-determined reference value or range of reference values or can be assessed at multiple time points (e.g. two, three, four, five or more) after a potential CNS injury and compared to a pre-determined reference value or to previously assessed values.
  • a biological sample for measuring levels or concentrations of inflammasome proteins can be obtained from a patient within one hour of a potential CNS injury to two weeks following a potential CNS injury. In some embodiments, the biological sample is obtained within one day, two days, three days, four days, five days, six days, seven days, ten days, or twelve days of a CNS injury or potential injury.
  • pre-determined reference value refers to a pre-determined value of the level or concentration of an inflammasome protein ascertained from a known sample.
  • the pre-determined reference value can reflect the level or concentration of an inflammasome protein in a sample obtained from a control subject (i.e., an uninjured, healthy subject).
  • the control subject may, in some embodiments, be age-matched to the patients being evaluated.
  • the measured level or concentration of at least one inflammasome protein is compared or determined relative to the level or concentration of said at least one inflammasome protein in a control sample (i.e. obtained from an uninjured subject).
  • the pre-determined reference value or range of reference values can reflect the level or concentration of an inflammasome protein in a sample obtained from a patient with a known severity of CNS injury as assessed by clinical measures or post mortem analysis.
  • a pre-determined reference value can also be a known amount or concentration of an inflammasome protein. Such a known amount or concentration of an inflammasome protein may correlate with an average level or concentration of the inflammasome protein from a population of control subjects or a population of patients with known levels of injury.
  • the pre-determined reference value can be a range of values, which, for instance, can represent a mean plus or minus a standard deviation or confidence interval.
  • a range of reference values can also refer to individual reference values for a particular inflammasome protein across various levels of CNS injury severity.
  • an increase in the level of one or more inflammasome proteins e.g., NLRP1 (NALP-1), ASC, or caspase-1) relative to a pre-determined reference value or range of reference values is indicative of a more severe central nervous system injury.
  • the method of assessing the severity of a CNS injury further comprises measuring the level or concentration of one or more proteins described in U.S. Patent Publication No. 2011/0177974, which is hereby incorporated by reference in its entirety, in addition to measuring the level or concentration of one or more inflammasome proteins.
  • the method further comprises measuring the level or concentration of one or more proteins selected from ubiquitin C-terminal hydrolase L1; vesicular membrane protein p-24; synuclein; microtubule-associated protein; synaptophysin; Vimentin; Synaptotagmin; Synaptojanin-2; Synapsin2; CRMP1, 2; Amphiphysin-1; PSD95; PSD-93; Calmodulin dependent protein kinase II (CAMPK)-alpha, beta, gamma; Myelin basic protein (MBP); Myelin proteolipid protein (PLP); Myelin Oligodendrocyte specific protein (MOSP); Myelin Oligodendrocyte glycoprotein (MOG); myelin associated protein (MAG); NF-H; NF-L; NF-M; BIII-tubulin-1 or combinations thereof in the biological sample obtained from the patient in addition to measuring the level or concentration of one or more inflammasome proteins.
  • proteins selected from ubiquitin C-terminal
  • the protein signature may comprise an elevated level of one or more of these proteins in addition to the elevated level of one or more inflammasome proteins.
  • the method further comprises measuring the level or concentration of one or more proteins selected from S-100 ⁇ , neuron-specific enolase, neurofilament light chain, glial fibrillary acidic protein (GFAP) or combinations thereof in the biological sample obtained from the patient in addition to measuring the level or concentration of one or more inflammasome proteins.
  • GFAP glial fibrillary acidic protein
  • the protein signature associated with a CNS injury or a more severe CNS injury comprises an elevated level of one or more proteins selected from 5-10013, neuron-specific enolase, neurofilament light chain, glial fibrillary acidic protein (GFAP) in addition to an elevated level of one or more inflammasome proteins (e.g. NLRP1 (NALP-1), ASC, or caspase-1).
  • GFAP glial fibrillary acidic protein
  • the methods of assessing the severity of a CNS injury in a patient or evaluating a patient suspected of having a CNS injury further comprise administering a neuroprotective treatment to the patient based on the measured level of said at least one inflammasome protein or when a protein signature associated with a CNS injury or a more severe CNS injury is identified.
  • neuroprotective treatments include drugs that reduce excitotoxicity, oxidative stress, and inflammation.
  • neuroprotective treatments include, but are not limited to, methylprednisolone, 17 ⁇ -estradiol, 17 ⁇ -estradiol, ginsenoside, progesterone, simvastatin, deprenyl, minocycline, resveratrol, and other glutamate receptor antagonists (e.g. NMDA receptor antagonists) and antioxidants.
  • neuroprotective treatments are neutralizing antibodies against an inflammasome protein or binding fragments thereof, such as those described in U.S. Patent Publication No. 2009/0104200, which is hereby incorporated by reference in its entirety.
  • the neuroprotective treatment is an anti-ASC antibody or fragment thereof.
  • Anti-ASC antibodies include antibodies that specifically bind to amino acid residues 178-193 of rat ASC (accession number BAC43754), e.g., amino acid sequence ALRQTQPYLVTDLEQS (SEQ ID NO:1), or antibodies that specifically bind to the amino acid sequence RESQSYLVEDLERS (SEQ ID NO:2) of human ASC.
  • the neuroprotective treatment is an anti-NLRP1 antibody or fragment thereof.
  • Suitable neutralizing anti-NLRP1 antibodies or fragments thereof include antibodies that specifically bind to the amino acid sequence CEYYTEIREREREKSEKGR (SEQ ID NO:3) of human NLRP1 or the amino acid sequence MEESQSKEESNTEG (SEQ ID NO: 4) of rat NLRP1.
  • the neutralizing antibodies or antibody fragments may be polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, single-chain variable fragments (scFvs) and the like.
  • Aptamers that specifically bind to an inflammasome protein or epitope thereof may also be suitable neuroprotective treatments. Neuroprotective treatments also encompass therapeutic regimens or rehabilitative procedures, such as hypothermia treatment.
  • the methods of evaluating a patient further comprise measuring the level of at least one inflammasome protein in a biological sample obtained from the patient following neuroprotective treatment, preparing a treatment protein signature associated with a positive response to the neuroprotective treatment, wherein the treatment protein signature comprises a reduced level of at least one inflammasome protein, and identifying patients exhibiting the presence of the treatment protein signature as responding positively to the neuroprotective treatment.
  • a reduction in the level, abundance, or concentration of one or more inflammasome proteins e.g. NLRP1, ASC, and caspase-1
  • the one or more inflammasome proteins measured in the sample obtained following treatment may be the same as or different than the inflammasome proteins measured in the sample obtained prior to treatment.
  • the inflammasome protein levels may also be used to adjust dosage or frequency of a neuroprotective treatment.
  • the present invention also provides a method of determining a prognosis for a patient with a central nervous system injury.
  • the method comprises providing a biological sample obtained from the patient within a week of injury, and measuring the level of at least one inflammasome protein in the biological sample to prepare an inflammasome protein profile as described above, wherein the inflammasome protein profile is indicative of the prognosis of the patient.
  • the biological sample is obtained from the patient within one week, within five days, or within three days of injury.
  • an increase in the level of one or more inflammasome proteins (e.g., NLRP1, ASC, caspase-1, or combinations thereof) relative to a pre-determined reference value or range of reference values is indicative of a poorer prognosis. For instance, an increase of about 20% to about 300% in the level of one or more inflammasome proteins relative to a pre-determined reference value or range of reference values is indicative of a poorer prognosis.
  • increased levels of caspase-1, particularly the p20 subunit of active caspase-1, relative to a pre-determined reference value or range of reference values acutely after injury (i.e. within a week of injury) is indicative of a poorer prognosis.
  • an elevated level of at least one inflammasome protein relative to a pre-determined reference value or range of reference values is predictive of the patient's recovery potential or long-term outcome as assessed by the Glasgow Outcome Scale (GOS).
  • GOS Glasgow Outcome Scale
  • the GOS is a scale that allows for the objective assessment of a patient's recovery following brain injury.
  • the scale is comprised of scores ranging from 1 to 5 with the following descriptions:
  • an elevated level of at least one inflammasome protein relative to a pre-determined reference value or range of reference values is predictive of the patient having a GOS score of 1 to 3 upon follow-up assessment (i.e. the patient having an unfavorable outcome, such as death or severe disability).
  • a reduced level of at least one inflammasome protein relative to a pre-determined reference value or range of reference values is predictive of the patient having a GOS score of 4 or 5 upon follow-up assessment (i.e. the patient having a favorable outcome, such as moderate to low disability).
  • the inventors have found that the CSF levels of one or more inflammasome proteins within three days following a CNS injury are useful for predicting the long-term outcome or recovery potential of the patient. Elevated inflammasome proteins levels correlate with unfavorable outcomes for the patient, whereas reduced or low inflammasome protein levels correlate with favorable outcomes for the patient (Example 3).
  • proteins of the invention and other marker proteins can be measured in a biological sample by various methods known to those skilled in the art.
  • proteins can be measured by methods including, but not limited to, liquid chromatography, gas chromatography, mass spectrometry, radioimmunoassays, immunofluorescent assays, FRET-based assays, immunoblot, ELISAs, or liquid chromatography followed by mass spectrometry (e.g., MALDI MS).
  • mass spectrometry e.g., MALDI MS.
  • kits for preparing an inflammasome protein profile associated with CNS injury such as spinal cord injury or traumatic brain injury.
  • the kits may include a reagent for measuring at least one inflammasome protein and instructions for measuring said at least one inflammasome protein for assessing the severity of a central nervous system injury in a patient.
  • a “reagent” refers to the components necessary for detecting or quantitating one or more proteins by any one of the methods described herein.
  • kits for measuring one or more inflammasome proteins can include reagents for performing liquid or gas chromatography, mass spectrometry, immunoassays, immunoblots, or electrophoresis to detect one or more inflammasome proteins as described herein.
  • the kit includes reagents for measuring one or more inflammasome proteins selected from NLRP1, ASC, caspase-1, or combinations thereof.
  • the kit comprises a labeled-binding partner that specifically binds to one or more inflammasome proteins, wherein said one or more inflammasome proteins are selected from the group consisting of NLRP1, ASC, caspase-1, and combinations thereof.
  • Suitable binding partners for specifically binding to inflammasome proteins include, but are not limited to, antibodies and fragments thereof, aptamers, peptides, and the like.
  • the binding partners for detecting NLPR1 are antibodies or fragments thereof, aptamers, or peptides that specifically bind to the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 of human NLRP1 and rat NLRP1, respectively.
  • the binding partners for detecting ASC are antibodies or fragments thereof, aptamers, or peptides that specifically bind to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 of rat ASC and human ASC, respectively.
  • Labels that can be conjugated to the binding partner include metal nanoparticles (e.g., gold, silver, copper, platinum, cadmium, and composite nanoparticles), fluorescent labels (e.g., fluorescein, Texas-Red, green fluorescent protein, yellow fluorescent protein, cyan fluorescent protein, Alexa dye molecules, etc.), and enzyme labels (e.g., alkaline phosphatase, horseradish peroxidase, beta-galactosidase, beta-lactamase, galactose oxidase, lactoperoxidase, luciferase, myeloperoxidase, and amylase).
  • metal nanoparticles e.g., gold, silver, copper, platinum, cadmium, and composite nanoparticles
  • fluorescent labels e.g., fluorescein, Texas-Red, green fluorescent protein, yellow fluorescent protein, cyan fluorescent protein, Alexa dye molecules, etc.
  • enzyme labels e.g., alkaline phosphata
  • the kit can include reagents for measuring one or more inflammasome proteins in CSF samples.
  • the kits can include reagents for measuring one or more inflammasome proteins in other patient samples including nerve tissue, CNS microdialysate, blood, saliva, serum, plasma, or urine.
  • the kits further comprise a set of reference values to which the measured level of one or more inflammasome proteins can be compared.
  • CSF samples from seven patients with SCI or control patients were analyzed for levels of nucleotide-binding leucine-rich repeat pyrin domain containing protein 1 (NLRP1; also known as NAcht leucine-rich-repeat protein 1 (NALP-1)), apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and caspase-1.
  • NLRP1 nucleotide-binding leucine-rich repeat pyrin domain containing protein 1
  • NALP-1 NAcht leucine-rich-repeat protein 1
  • ASC caspase recruitment domain
  • caspase-1 The American Spinal Cord Injury Association (ASIA) scale of the SCI patients at admission to the emergency department ranged from AIS A to B. Information regarding the diagnosis, procedures and outcomes of the patients is shown in Table 1. None of the patients had any complications.
  • CSF from uninjured individuals was obtained as a control from three males and two females ranging from 67 to 91 years old.
  • CSF samples were prepared with Laemali buffer Immunoblot analysis was carried with the Criterion system (Bio-Rad) as described previously (de Rivero Vaccari et al., 2008) using antibodies (1:1000 dilution) to NLRP1 (Bethyl Laboratories), Caspase-1 (Imgenex) and ASC (Santa Cruz).
  • Proteins were resolved in 14-20% TGX Criterion precasted gels (Bio-Rad), transferred to polyvinylidene difluoride (PVDF) transfer membranes (Tropifluor—Applied Biosystems) and placed in blocking buffer (PBS, 0.1% Tween-20, 0.4% I-Block (Applied Biosystems) and then incubated for one hour with primary antibodies. Membranes were then incubated for one hour with anti-mouse, anti-rat or anti-rabbit horseradish peroxidase (HRP)-linked antibodies. Signal visualization was performed by enhanced chemiluminescence.
  • PVDF polyvinylidene difluoride transfer membranes
  • Spinal cord sections were obtained from nine decedents (8 males and 1 female with ages ranging from 20 to 77 years) who had injury to the spinal cord due to vertebral fractures.
  • the spinal cord injury was assessed microscopically, using bright field optics, by examining one H&E or H&E/DAB-stained section from the lesion center of each case or from cervical, thoracic and lumbar sections from control cases.
  • the spinal cord injuries were classified on the basis of their histological appearance as “contusion/cyst,” massive compression, or laceration (Fleming et al., 2006).
  • Contusional injuries were characterized by an intact pia and relative preservation of the anatomical relations of various elements of the spinal cord, and variable degrees of injury ranging from involvement of the entire cross-sectional area to large usually asymmetric areas of tissue damage.
  • Massive compression injuries were characterized by disruption of the pia and severe distortion and disruption of spinal cord parenchyma.
  • Laceration injuries which by definition were perforating or penetrating injuries caused by weapons or projectiles, were associated with breaching of the pia and linear tearing of the cord tissue.
  • tissue samples from the center of injury and at various distances above and below the injury were obtained.
  • the data from tissue from the center of the lesion were used to compare the inflammatory responses between cases whereas those from the remote, uninjured segments of the spinal cord served as within-case controls. Between-case comparison of the remote samples was not possible because, for different cases, the distance of these samples from the lesion center was variable.
  • NLRP1 is expressed in neurons of the ventral horn (black arrows), myelinated axons (arrow heads) and oligodendrocytes (yellow arrows) in injured spinal cords ( FIG. 2 ). Moreover, NLRP1 immunoreactivity in areas of the penumbra (C7) was higher than in areas distant to the epicenter (L2).
  • DAB immunoreactivity for caspase-1 was detected in swollen axons (spheroids, blue arrows) ( FIG. 2 ), and arterioles (not shown). At areas of the penumbra, caspase-1 staining is present in motor neurons (black arrows) of the ventral horn, and in the white matter in oligodendrocytes (yellow arrows). Caspase-1 immunoreactivity in oligodendrocytes (yellow arrows) was the same at all levels of the spinal cords examined, regardless of proximity to the epicenter. At areas distant to the epicenter (T12), caspase-1 was also present in motor neurons (black arrows) but with decreased immunoreactivity than the penumbra (C7). This finding indicates that caspase-1 immunoreactivity in neurons decreases as the distance to the epicenter increases, similarly to NLRP1.
  • ASC a subset of neurons in the ventral horn (black arrows) and white matter oligodendrocytes (yellow arrow) showed ASC immunoreactivity.
  • ASC was also present in macrophages/microglia at the epicenter (blue arrow heads).
  • ASC immunoreactivity was also detected in the substantia gelatinosa (dorsal horn) at C7 and L2 (not shown).
  • Neuroinflammation has been considered to play a critical role in the pathogenesis of SCI and TBI, but the role of the innate immune response has not been examined directly.
  • the innate immune system senses microbial and viral pathogen-associated molecular patterns and danger signals released from damaged or stressed cells to trigger conserved intracellular signaling pathways that drive proinflammatory responses that are critical for productive innate and adaptive immunity. Excessive inflammatory responses become deleterious leading to tissue destruction.
  • the results of this experiment provide evidence demonstrating that the NLRP1 inflammasome signaling system is activated in the innate immune response in damaged human spinal cord and brain tissue after trauma.
  • CSF samples were collected from 23 traumatic brain injury (TBI) patients on the day of injury and up to three days after the injury and analyzed by immunoblot for levels of NALP-1 (also known as NLRP1), ASC, and caspase-1.
  • TBI traumatic brain injury
  • Cerebrospinal fluid samples were collected within 12 hours of injury and up to 72 hours after injury. Samples were centrifuged at 2000 g for 10 minutes at 4° C. to pellet cellular bodies and debris. Supernatants were resolved by gel electrophoresis and immunoblotted as previously described (de Rivero Vaccari et al., 2008). Quantification of band density was performed with UNSCAN-IT gel digitizing software (Silk Scientific). Due to the low volume of sample available, NALP-1 was analyzed in 6 of the 9 controls, caspase-1 was analyzed in 43 of the 45 TBI samples, and NALP-1 was analyzed in 42 of the 45 TBI samples.
  • inflammasome proteins e.g. ASC, NALP-1, and caspase-1
  • ASC inflammasome proteins
  • NALP-1 e.g., NALP-1
  • caspase-1 e.g., caspase-1
  • Elevation of these proteins likely reflects the extent of neuroinflammation, suggesting that inflammasome proteins can serve as acute biomarkers of CNS injury.
  • CSF biomarkers are more specific indicators of neuropathology than serum biomarkers.
  • Cerebrospinal fluid directly bathes the brain, closely reflecting the extracellular milieu and biochemical changes that are specific to the CNS. Sampling the CSF eliminates influences of multiorgan trauma or other systemic pathology represented in the serum, which is significant as patients with TBI often present with trauma to other organ systems.
  • ASC active caspase-1
  • NALP-1 NALP-1 in the CSF.
  • therapeutic hypothermia attenuates the endogenous inflammatory response of the CNS to TBI by decreasing cytokine production and reducing activation of astrocytes and microglia (Aibiki et al., 1999; Goss et al., 1995; Kumar et al., 1997; Truettner et al., 2005), and cortical neurons exposed to moderate hypothermia in culture show a decrease in activation of the inflammasome (Tomura et al., in press).
  • ASC, active caspase-1, and NALP-1 can serve as objective, biochemical indicators of treatment efficacy for patients with CNS injury.
  • inflammasome proteins such as caspase-1
  • CSF caspase-1 levels obtained from pediatric patients who received hypothermia treatment following TBI were compared to those obtained from pediatric patients who did not receive treatment following TBI.
  • Cerebrospinal fluid of pediatric patients (ages 0.1 to 16 years) was obtained at different times after traumatic brain injury (day 1, 2 and 3). Patients were divided into those that received hypothermia treatment and those who did not (normothermia). As shown in FIG. 6 , the data indicate that within 24 hours after injury the levels of caspase-1 were lower in the hypothermia group when compared to the normothermia group.
  • post-traumatic therapeutic hypothermia lowers the levels of caspase-1 activation after brain injury, consistent with findings that those patients that receive hypothermia treatment present better outcomes when compared to those patients who do not get the hypothermia treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US14/376,383 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury Abandoned US20150185232A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/376,383 US20150185232A1 (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595254P 2012-02-06 2012-02-06
US14/376,383 US20150185232A1 (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury
PCT/US2013/024941 WO2013119673A1 (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2013/024941 A-371-Of-International WO2013119673A1 (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury
US17/921,600 Continuation-In-Part US20230296626A1 (en) 2020-04-27 2021-04-27 Compositions and methods for treating inflammasome related diseases or conditions
PCT/US2021/029419 Continuation-In-Part WO2021222263A2 (en) 2012-02-06 2021-04-27 Compositions and methods for treating inflammasome related diseases or conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/214,868 Continuation US20170003303A1 (en) 2012-02-06 2016-07-20 Innate Immune Proteins As Biomarkers for CNS Injury

Publications (1)

Publication Number Publication Date
US20150185232A1 true US20150185232A1 (en) 2015-07-02

Family

ID=48947960

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/376,383 Abandoned US20150185232A1 (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury
US15/214,868 Abandoned US20170003303A1 (en) 2012-02-06 2016-07-20 Innate Immune Proteins As Biomarkers for CNS Injury
US16/986,904 Abandoned US20200363432A1 (en) 2012-02-06 2020-08-06 Innate immune proteins as biomarkers for cns injury
US18/347,108 Pending US20230349929A1 (en) 2012-02-06 2023-07-05 Innate immune proteins as biomarkers for cns injury

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/214,868 Abandoned US20170003303A1 (en) 2012-02-06 2016-07-20 Innate Immune Proteins As Biomarkers for CNS Injury
US16/986,904 Abandoned US20200363432A1 (en) 2012-02-06 2020-08-06 Innate immune proteins as biomarkers for cns injury
US18/347,108 Pending US20230349929A1 (en) 2012-02-06 2023-07-05 Innate immune proteins as biomarkers for cns injury

Country Status (6)

Country Link
US (4) US20150185232A1 (enExample)
EP (1) EP2812697B1 (enExample)
JP (1) JP6170071B2 (enExample)
CA (1) CA2863417C (enExample)
ES (1) ES2630905T3 (enExample)
WO (1) WO2013119673A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109406795A (zh) * 2018-11-20 2019-03-01 昆明医科大学 一种轻型脑外伤的血清分子诊断标记物及应用
WO2019199871A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of neurofilament light chain in physiological samples
WO2021071934A1 (en) * 2019-10-07 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Polymeric methylprednisolone conjugates and uses thereof
US11275092B2 (en) 2011-04-12 2022-03-15 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US20230296626A1 (en) * 2020-04-27 2023-09-21 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129788A4 (en) * 2014-04-08 2018-04-04 University of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
WO2018126009A1 (en) 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
EP3685169A4 (en) * 2017-09-20 2021-09-08 University of Miami PROCESS FOR DETECTION OF INFLAMMASOME PROTEINS AS BIOMARKERS OF NEUROLOGICAL DISORDERS
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
WO2020157206A1 (en) * 2019-01-31 2020-08-06 University Of Geneva Prospective markers in traumatic brain injury (tbi)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022156A2 (en) * 2002-09-04 2004-03-18 Washington University Methods for treating central nervous system damage
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
JP2011511301A (ja) * 2008-02-04 2011-04-07 バンヤン・バイオマーカーズ・インコーポレイテッド 脳損傷を診断または治療するための方法
WO2010008594A1 (en) * 2008-07-18 2010-01-21 Oxygen Biotherapeutics, Inc. Method of treating traumatic brain injury
US20120177632A1 (en) * 2011-01-10 2012-07-12 Shinohara Mari L Methods of optimizing disease treatment

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11275092B2 (en) 2011-04-12 2022-03-15 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
WO2019199871A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of neurofilament light chain in physiological samples
WO2019199869A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in physiological samples
US20220229073A1 (en) * 2018-04-10 2022-07-21 Quanterix Corporation Quantification of neurofilament light chain in physiological samples
US12111324B2 (en) 2018-04-10 2024-10-08 Quanterix Corporation Quantification of biomarkers present in dried physiological samples
US12130294B2 (en) 2018-04-10 2024-10-29 Quanterix Corporation Quantification of biomarkers present in physiological samples
US12287343B2 (en) * 2018-04-10 2025-04-29 Quanterix Corporation Quantification of neurofilament light chain in physiological samples
CN109406795A (zh) * 2018-11-20 2019-03-01 昆明医科大学 一种轻型脑外伤的血清分子诊断标记物及应用
WO2021071934A1 (en) * 2019-10-07 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Polymeric methylprednisolone conjugates and uses thereof
US20230296626A1 (en) * 2020-04-27 2023-09-21 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions

Also Published As

Publication number Publication date
EP2812697A1 (en) 2014-12-17
JP2015508887A (ja) 2015-03-23
WO2013119673A1 (en) 2013-08-15
EP2812697B1 (en) 2017-03-22
ES2630905T3 (es) 2017-08-25
US20170003303A1 (en) 2017-01-05
CA2863417C (en) 2020-07-28
CA2863417A1 (en) 2013-08-15
EP2812697A4 (en) 2015-08-26
JP6170071B2 (ja) 2017-07-26
US20230349929A1 (en) 2023-11-02
US20200363432A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
US20230349929A1 (en) Innate immune proteins as biomarkers for cns injury
Hong et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
CA2877975C (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
WO2011160096A2 (en) Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
US20140370531A1 (en) Method of diagnosing mild traumatic brain injury
EP2591367B1 (en) Method for diagnosis
KR20200088299A (ko) 신경학적 장애의 바이오마커로서 인플라마솜 단백질의 검출 방법
US20120295281A1 (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
US20240060995A1 (en) Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
Tovi et al. Prestin autoantibodies screening in idiopathic sudden sensorineural hearing loss
US20240142471A1 (en) Test for mild cognitive impairment
Suzuki et al. Ratio of alpha 2-macroglobulin levels in cerebrospinal fluid and serum: an expression of neuroinflammation in acute disseminated encephalomyelitis
Ashaat et al. Altered adaptive cellular immune function in a group of Egyptian children with autism
Nikolaus et al. Presence of anti-neuronal antibodies in children with neurological disorders beyond encephalitis
WO2023212583A9 (en) Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
US20220412994A1 (en) Biomarker of drug-induced cellular toxicity and depression
Etemadifar et al. Seroprevalence of NMO-IgG among patients with neuromyelitis optica and opticospinal multiple sclerosis
Li et al. Immune-related biomarkers in the neuromyelitis optica spectrum disorder; pathogenesis and therapeutic approaches
US11609236B2 (en) Blood biomarkers for severe traumatic brain injuries
Casemore Biomarkers of Dry Eye Disease
鈴木雄一 Ratio of alpha2-macroglobulin levels in cerebrospinal fluid and serum: an expression of neuroinflammation in acute disseminated encephalomyelitis
Ouellet et al. Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model
WO2022214717A1 (es) Biomarcador en líquido cefalorraquídeo para enfermedad de alzheimer
Traboulsee et al. Epidemiology & Registry

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: UNIVERSITY OF MIAMI, FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KEANE, ROBERT W.;DIETRICH, W. DALTON;DE RIVERO VACCARI, JUAN PABLO;AND OTHERS;SIGNING DATES FROM 20120309 TO 20120315;REEL/FRAME:045873/0679